ReP USP - Resultado da busca

Artigo de periodico
Treatment effect of alirocumab according to age group, smoking status, and hypertension: pooled analysis from 10 randomized ODYSSEY studies (2019)
Raal, Frederick J; Tuomilehto, Jaakko; Sposito, Andrei C; Fonseca, Francisco A; Averna, Maurizio; Farnier, Michel; Santos Filho, Raul Dias dos ; Ferdinand, Keith C; Wright, R. Scott; Navarese, Eliano Pio
Source: Journal of clinical lipidology. Unidade: FM
Subjects: ENZIMAS PROTEOLÍTICAS, TABAGISMO, HIPERTENSÃO, FATORES ETÁRIOS, LIPOPROTEÍNAS, HIPERCOLESTEROLEMIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RAAL, Frederick J et al. Treatment effect of alirocumab according to age group, smoking status, and hypertension: pooled analysis from 10 randomized ODYSSEY studies. Journal of clinical lipidology, v. 13, n. 5, p. 735-743, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.jacl.2019.06.006. Acesso em: 01 nov. 2024.
APA
Raal, F. J., Tuomilehto, J., Sposito, A. C., Fonseca, F. A., Averna, M., Farnier, M., et al. (2019). Treatment effect of alirocumab according to age group, smoking status, and hypertension: pooled analysis from 10 randomized ODYSSEY studies. Journal of clinical lipidology, 13( 5), 735-743. doi:10.1016/j.jacl.2019.06.006
NLM
Raal FJ, Tuomilehto J, Sposito AC, Fonseca FA, Averna M, Farnier M, Santos Filho RD dos, Ferdinand KC, Wright RS, Navarese EP. Treatment effect of alirocumab according to age group, smoking status, and hypertension: pooled analysis from 10 randomized ODYSSEY studies [Internet]. Journal of clinical lipidology. 2019 ; 13( 5): 735-743.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.jacl.2019.06.006
Vancouver
Raal FJ, Tuomilehto J, Sposito AC, Fonseca FA, Averna M, Farnier M, Santos Filho RD dos, Ferdinand KC, Wright RS, Navarese EP. Treatment effect of alirocumab according to age group, smoking status, and hypertension: pooled analysis from 10 randomized ODYSSEY studies [Internet]. Journal of clinical lipidology. 2019 ; 13( 5): 735-743.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1016/j.jacl.2019.06.006
Artigo de periodico
Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients (2017)
Ridker, Paul M.; Revkin, James; Amarenco, Pierre; Brunell, Robert; Curto, Madelyn; Civeira, Fernando; Flather, Marcus; Glynn, Robert J.; Gregoire, Jean; Jukema, J. Wouter; Karpov, Yuri; Kastelein, John J.P.; Koenig, Wolfgang; Lorenzatti, Alberto; Manga, Pravin; Masiukiewicz, Urszula; Miller, Michael; Mosterd, Arend; Murin, Jan; Nicolau, Jose C.; Nissen, Steven; Ponikowski, Piotr; Santos, Raul D.; Schwartz, Pamela F.; Soran, Handrean; White, Harvey; Wright, R. Scott; Vrablik, Michal; Yunis, Carla; Shear, Charles L.; Tardif, Jean-Claude
Source: The New England Journal of Medicine. Unidade: FM
Subjects: COLESTEROL, PLACEBO, ANTICORPOS MONOCLONAIS, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RIDKER, Paul M. et al. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. The New England Journal of Medicine, v. 376, n. 16, p. 1527-1539, 2017Tradução . . Disponível em: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1701488. Acesso em: 01 nov. 2024.
APA
Ridker, P. M., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., et al. (2017). Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. The New England Journal of Medicine, 376( 16), 1527-1539. doi:10.1056/NEJMoa1701488
NLM
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif J-C. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients [Internet]. The New England Journal of Medicine. 2017 ; 376( 16): 1527-1539.[citado 2024 nov. 01 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1701488
Vancouver
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif J-C. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients [Internet]. The New England Journal of Medicine. 2017 ; 376( 16): 1527-1539.[citado 2024 nov. 01 ] Available from: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1701488
Artigo de periodico
Effects of dalcetrapib in patients with a recent acute coronary syndrome (2012)
Schwartz, Gregory G; Olsson, Anders G; Abt, Markus; Ballantyne, Christie M; Barter, Philip J; Brumm, Jochen; Chaitman, Bernard R; Holme, Ingar M; Kallend, David; Leiter, Lawrence A; Leitersdorf, Eran; McMurray, John J. V; Mundl, Hardi; Nicholls, Stephen J; Shah, Prediman K; Tardif, Jean-Claude; Wright, R. Scott; Marin Neto, Jose Antonio
Source: The New England Journal of Medicine. Unidade: FMRP
Subjects: CORONARIOPATIA, DOENÇAS CARDIOVASCULARES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SCHWARTZ, Gregory G et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. The New England Journal of Medicine, v. 367, n. 22, p. 2089-2099, 2012Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa1206797. Acesso em: 01 nov. 2024.
APA
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., et al. (2012). Effects of dalcetrapib in patients with a recent acute coronary syndrome. The New England Journal of Medicine, 367( 22), 2089-2099. doi:10.1056/NEJMoa1206797
NLM
Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Mundl H, Nicholls SJ, Shah PK, Tardif J-C, Wright RS, Marin Neto JA. Effects of dalcetrapib in patients with a recent acute coronary syndrome [Internet]. The New England Journal of Medicine. 2012 ; 367( 22): 2089-2099.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1056/NEJMoa1206797
Vancouver
Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Mundl H, Nicholls SJ, Shah PK, Tardif J-C, Wright RS, Marin Neto JA. Effects of dalcetrapib in patients with a recent acute coronary syndrome [Internet]. The New England Journal of Medicine. 2012 ; 367( 22): 2089-2099.[citado 2024 nov. 01 ] Available from: https://doi.org/10.1056/NEJMoa1206797

USP Schools

ReP

Filtros

Authors

Subjects

Indexado em